<DOC>
	<DOCNO>NCT00122590</DOCNO>
	<brief_summary>This Cophar2 study trial evaluates repeat early therapeutic drug monitoring , week 2 24 , initiation HAART include either indinavir/r , lopinavir/r new 625 mg formulation nelfinavir twice-a-day ( bid ) . If trough concentration range give protease inhibitor ( PI ) , PI dose adjust .</brief_summary>
	<brief_title>Evaluation Therapeutic Drug Monitoring Protease Inhibitors Virologic Success Tolerance Highly Active Antiretroviral Therapy ( HAART )</brief_title>
	<detailed_description>Because large pharmacokinetic inter-patient variability protease inhibitor ( PI ) , therapeutic drug monitoring ( TDM ) protease inhibitor ( PI ) propose improve efficacy tolerance PI-containing HAART . The objective Cophar2 trial evaluate feasibility impact early therapeutic drug monitor PI-naive HIV-1 infect patient order warrant virological success safety HAART . It prospective , open , multicenter trial repeat early TDM ( week 2 , 8 16 , 24 ) initiation HAART include either indinavir/r ( IDV ) , lopinavir/r ( LPV ) new 625 mg formulation nelfinavir ( NFV ) bid . It plan include 99 PI-na√Øve HIV-1 infect patient 18 year old , 33 PI . Concentrations measure HPLC center . If trough concentration range 150-500 , 2500-7000 1500-5500 ng/ml IDV , LPV NFV respectively , PI dose adjust possibly first 24 week follow-up . Adjustments do step one pill ( 200 , 133/33 250 mg IDV , LPV/r NFV , respectively ) bid . Failure strategy define either two consecutive viral load 200 copies/ml week 16 48 , validate PI-related adverse event grade III IV grade II diarrhoea renal lithiasis . Patients without adverse event week 16 define assessable least virological assessment week 16 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Patients infect HIV1 Needing antiretroviral treatment accord standard care HIV viral load great 1000 copies/ml Beginning treatment contain PI ( indinavir without ritonavir , nelfinavir , lopinavir + ritonavir ) 2 reverse transcriptase inhibitor PInaive Antiretroviral treatmentnaive already treated reverse transcriptase inhibitor viral genotypic test show 2 major mutation ( include T215Y/F , Q151M , M184V/I , V75M/S , L74V ) 3 nucleoside analogue still active except didanosine . Pregnant woman nurse mother Acute HIV infection Diabetes Renal insufficiency creatinine clearance 30 ml/min Cardiac insufficiency Hepatic insufficiency TP 60 % Treatment know interaction PI Chemotherapy Kaposi 's sarcoma , lymphoma , neoplasia Treatment contain interferon ( INF ) interleukin2 ( IL2 ) HIV immune vaccine Treatment hypolipemic drug Laxative treatment Previous renal colic Diarrhoea 5 stools/day since one week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>protease inhibitor</keyword>
	<keyword>nelfinavir</keyword>
	<keyword>lopinavir</keyword>
	<keyword>indinavir</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>